From October 25-28 Delta4 attended the (virtual) BIO-EUROPE conference, the largest partnering event in Europe dedicated to the global biotechnology industry.
We presented the exciting progress that Delta4 has made over the course of the year as well as the plans going forward.
Furthermore, we discussed concrete cooperation opportunities with a number of Pharma and BioTech firms from Europe, the USA and Asia. After proof of concept in 2020, a substantial Series A investment in early 2021, and a considerate scaling of the company in mid-2021, this was the right time to further engage with potential partners and clients on a broader front.
Going into 2022 we expect several deeper relationships to be firmed up and we are looking forward to once again contributing real and tangible value to our current and future partners.
About Delta4’s Drug Discovery Platform
Delta4’s drug discovery platform was successfully applied in contract research for global pharma and biotechnology companies. The platform integrates in-silico drug discovery and big data analysis with extensive expertise in molecular biology and clinical development. Due to its unique technology, Delta4 delivers not only drug candidates but also a mechanistic hypothesis about the underlying mode of action, significantly increasing their value for pharmaceutical development.
Contact Delta 4 GmbH, Kurt Herpel, CEO, Alser Straße 23/30, 1080 Vienna Austria, office@delta4.ai, +41 79 874 13 22
